2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Mineral Metabolism
  5. Hypercalcemia

Hypercalcemia

Hypercalcemia is a common clinical condition characterized by elevated serum calcium levels, typically above the normal range of 2.1–2.6 mmol/L, resulting from excessive calcium entry into the extracellular fluid or impaired renal excretion. The most frequent causes are primary hyperparathyroidism and malignancy-associated hypercalcemia, together accounting for over 90% of cases. These conditions often lead to increased bone resorption or impaired kidney function. Early symptoms are frequently mild and nonspecific, including constipation, nausea, vomiting, abdominal pain, and loss of appetite, while more severe manifestations—such as confusion, depression, weakness, kidney stones, bone pain, and abnormal heart rhythms—may occur with higher or rapidly rising calcium levels. In extreme cases, hypercalcemia can lead to life-threatening complications like cardiac arrest. Although many patients with mild hypercalcemia remain asymptomatic, it remains a significant metabolic disorder requiring timely diagnosis and management to prevent long-term complications such as bone demineralization and renal impairment.

References:

Hypercalcemia (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0805A
    Alisol B 18649-93-9 99.57%
    Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a Ki of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.
    Alisol B
  • HY-16498
    Tigapotide 848084-83-3
    Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia.
    Tigapotide